Tenon Medical, Inc. (TNONW) — SEC Filings
Tenon Medical, Inc. (TNONW) — 46 SEC filings. Latest: 8-K (Nov 17, 2025). Includes 21 8-K, 6 10-Q, 4 8-K/A.
View Tenon Medical, Inc. on SEC EDGAR
Overview
Tenon Medical, Inc. (TNONW) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Nov 17, 2025: Tenon Medical, Inc. entered into a material definitive agreement on November 10, 2025, related to unregistered sales of equity securities. The company, incorporated in Delaware, filed this 8-K report on November 17, 2025, detailing these events. The filing also includes financial statements and exhi
Sentiment Summary
Across 46 filings, the sentiment breakdown is: 7 bearish, 38 neutral, 1 mixed. The dominant filing sentiment for Tenon Medical, Inc. is neutral.
Filing Type Overview
Tenon Medical, Inc. (TNONW) has filed 21 8-K, 6 10-Q, 4 8-K/A, 2 DEF 14A, 4 S-1, 2 10-K, 3 S-1/A, 2 SC 13G, 2 SC 13G/A with the SEC between Jan 2024 to Nov 2025.
Filings by Year
Recent SEC Filings (46)
Risk Profile
Risk Assessment: Of TNONW's 39 recent filings, 6 were flagged as high-risk, 24 as medium-risk, and 9 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $2,463,000 |
| Net Income | -$9,724,000 |
| EPS | -$0.40 |
| Debt-to-Equity | 1.16 |
| Cash Position | $3,442,000 |
| Operating Margin | -80.5% |
| Total Assets | $10,366,000 |
| Total Debt | $5,568,000 |
Key Executives
- Steven M. Foster
- Ross D. Carmel
- Jeffrey P. Wofford
- Dr. David L. Johnson
- Mr. David L. Johnson
- Robert L. Johnson
- Michael A. Johnson
Industry Context
Tenon Medical operates in the highly competitive medical device sector, specifically focusing on spinal fusion solutions. The industry is characterized by rapid technological advancements, significant R&D investment, and stringent regulatory hurdles. Companies often pursue strategic acquisitions to expand product portfolios and market reach, as seen with Tenon's recent acquisitions.
Top Tags
equity-sale (9) · material-agreement (7) · sec-filing (6) · amendment (4) · corporate-governance (4) · 10-Q (4) · medical-devices (4) · delisting (4) · Medical Devices (3) · shareholder-vote (3)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net Loss (Q3 2025) | $3.339M | Increased from $3.184M in Q3 2024, indicating worsening profitability. |
| Net Loss (9 Months 2025) | $9.724M | Improved from $10.586M in 9 months 2024, but still a significant loss. |
| Revenue (Q3 2025) | $1.173M | Increased from $887K in Q3 2024, showing quarterly growth. |
| Revenue (9 Months 2025) | $2.463M | Slightly decreased from $2.507M in 9 months 2024, indicating flat year-to-date performance. |
| Cash and Cash Equivalents (Sep 30, 2025) | $3.442M | Decreased significantly from $6.535M at Dec 31, 2024, highlighting liquidity concerns. |
| Net Cash Used in Operating Activities (9 Months 2025) | $8.521M | Increased from $7.101M in 9 months 2024, showing accelerating cash burn. |
| Goodwill (Sep 30, 2025) | $2.407M | Resulted from the SImmetry Acquisition, reflecting acquisition premium. |
| Contingent Consideration (Sep 30, 2025) | $1.011M | Liability from the SiVantage acquisition, adding future payment obligations. |
| Common Stock Shares Outstanding (Nov 13, 2025) | 8,605,740 | Increased from 3,138,804 at Dec 31, 2024, indicating significant dilution. |
| Net Loss Per Share (Q3 2025) | $0.40 | Lower than $3.63 in Q3 2024 due to increased share count, masking the absolute loss increase. |
| Revenue for Q2 2025 | $564 thousand | decreased from $901 thousand in Q2 2024, a 37.4% decline |
| Revenue for H1 2025 | $1,290 thousand | decreased from $1,620 thousand in H1 2024, a 20.4% decline |
| Net Loss for Q2 2025 | $(2,769) thousand | improved from $(3,826) thousand in Q2 2024 |
| Net Loss for H1 2025 | $(6,385) thousand | improved from $(7,402) thousand in H1 2024 |
| Cash and Cash Equivalents at June 30, 2025 | $7,846 thousand | increased from $6,535 thousand at December 31, 2024 |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Tenon Medical, Inc. (TNONW)?
Tenon Medical, Inc. has 46 recent SEC filings from Jan 2024 to Nov 2025, including 21 8-K, 6 10-Q, 4 8-K/A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of TNONW filings?
Across 46 filings, the sentiment breakdown is: 7 bearish, 38 neutral, 1 mixed. The dominant sentiment is neutral.
Where can I find Tenon Medical, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Tenon Medical, Inc. (TNONW) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Tenon Medical, Inc.?
Key financial highlights from Tenon Medical, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for TNONW?
The investment thesis for TNONW includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Tenon Medical, Inc.?
Key executives identified across Tenon Medical, Inc.'s filings include Steven M. Foster, Ross D. Carmel, Jeffrey P. Wofford, Dr. David L. Johnson, Mr. David L. Johnson and 2 others.
What are the main risk factors for Tenon Medical, Inc. stock?
Of TNONW's 39 assessed filings, 6 were flagged high-risk, 24 medium-risk, and 9 low-risk.
What are recent predictions and forward guidance from Tenon Medical, Inc.?
Forward guidance and predictions for Tenon Medical, Inc. are extracted from SEC filings as they are enriched.